Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.70 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.70 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.70 |
| ▸ | MARS1 | P56192 | 3/20 | 0.77 |
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.76 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.76 |
| ▸ | NSD2 | O96028 | 4/20 | 0.76 |
| ▸ | SETD7 | Q8WTS6 | 4/20 | 0.76 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.76 |
| ▸ | NNMT | P40261 | 3/20 | 0.76 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.76 |
| ▸ | FASN | P49327 | 3/20 | 0.76 |
| ▸ | TRDMT1 | O14717 | 2/20 | 0.76 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.76 |
| ▸ | INMT | O95050 | 2/20 | 0.76 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.76 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.76 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL27500408 | 1.00 | MARS1 (0.77) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL3014288 | 1.00 | MARS1 (0.77) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL27683410 | 0.99 | MARS1 (0.75) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL28733069 | 0.97 | MARS1 (0.72) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL28535357 | 0.97 | MARS1 (0.72) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL28544361 | 0.97 | MARS1 (0.72) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL29735027 | 0.93 | MARS1 (0.74) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL25303131 | 0.93 | MARS1 (0.67) | MARS1DOT1LCARM1NSD2SETD7 | |
| Racemethionine SCHEMBL28493813 | 0.92 | MARS1 (0.75) | MARS1DOT1LCARM1NSD2SETD7 | |
| Adenosine SCHEMBL20490833 | 0.91 | MARS1 (0.65) | MARS1DOT1LCARM1NSD2SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563375-A | Tungsten barrier polishing slurry composition | 凯斯科技股份有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-104178540-A | Method for synthesizing ademetionine by biological catalytic process | ZHEJIANG ZHENYUAN PHARMACEUTICAL CO LTD | 2014-12-03 | — | — | CN | claimed |
| CN-101392230-B | Recombinant escherichia coli for expressing adenosylmethionine synthetase | BEIJING KAWIN TECHNOLOGY CO LTD | 2012-05-23 | — | — | CN | claimed |
| CN-102458497-A | Catheter balloon coated with shellac and paclitaxel | EUROCOR GMBH | 2012-05-16 | — | — | CN | claimed |
| CN-1955306-B | Method of saccharomycetes bio-synthesing, of producing optical pure adenosine methionine and its culture solution | SHANGHAI INST PHARM INDUSTRY | 2011-03-16 | — | — | CN | claimed |
| CN-101392230-A | Recombinant escherichia coli for expression of adenomethionine synthetase | BEIJING KAWIN TECHNOLOGY CO LT (CN) | 2009-03-25 | — | — | CN | claimed |
| CN-100465282-C | Method for synthesizing adenosine methionine utilizing biological catalysis | JILIN QIJIAN BIOLOG TECHNOLOGY (CN) | 2009-03-04 | — | — | CN | claimed |
| CN-1955306-A | Method of saccharomycetes bio-synthesing, producing optical pure adenosine methionine and its culture solution | SHANGHAI MEDICIAL INDUSTRY INS (CN) | 2007-05-02 | — | — | CN | claimed |
| CN-1814774-A | Method for synthesizing adenosine methionine utilizing biological catalysis | QIJIAN BIOLOG TECHNOLOGY CO LT (CN) | 2006-08-09 | — | — | CN | claimed |
| CN-1665554-A | Compounds and method for coating surfaces in a haemocompatible manner | HEMOTEQ GMBH (DE) | 2005-09-07 | — | — | CN | claimed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024100025-A1 | IMPROVED VACCINE | ONCODNA (BE) | 2024-05-16 | — | — | WO | disclosed |
| EP-4364752-A1 | IMPROVED VACCINE | OncoDNA (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2023123309-A1 | METHOD FOR MEASURING AMINO ACID IMPURITIES IN SPECIAL SOLVENT FOR BUTANEDISULFONIC ACID ADENOSINE METHIONINE FOR INJECTION | 浙江海正药业股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-1955306-A | Method of saccharomycetes bio-synthesing, producing optical pure adenosine methionine and its culture solution | SHANGHAI MEDICIAL INDUSTRY INS (CN) | 2007-05-02 | — | — | CN | disclosed |
| CN-1955306-A | Method of saccharomycetes bio-synthesing, producing optical pure adenosine methionine and its culture solution | SHANGHAI MEDICIAL INDUSTRY INS (CN) | 2007-05-02 | — | — | CN | disclosed |
| CN-1814774-A | Method for synthesizing adenosine methionine utilizing biological catalysis | QIJIAN BIOLOG TECHNOLOGY CO LT (CN) | 2006-08-09 | — | — | CN | disclosed |
| CN-1814774-A | Method for synthesizing adenosine methionine utilizing biological catalysis | QIJIAN BIOLOG TECHNOLOGY CO LT (CN) | 2006-08-09 | — | — | CN | disclosed |
| CN-1814774-A | Method for synthesizing adenosine methionine utilizing biological catalysis | QIJIAN BIOLOG TECHNOLOGY CO LT (CN) | 2006-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | ADORA3 4120/4885ADORA2A 2424/4885ADORA2B 3391/4885 |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | ADORA3 4120/4885ADORA2A 2424/4885ADORA2B 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.